Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Our innovative technological approach is to target tumors overexpressing matricellular protein thrombospondin-1 (TSP-1).
Our long-term vision is to develop personalized immunotherapy approaches combining a proprietary therapeutic peptide targeting TSP-1 (namely TAX2 peptide) and a companion diagnostic kit, which may enable patient stratification for TAX2 therapy eligibility based on the monitoring of circulating TSP-1.
Location: France, Grand Est, Reims
Member count: 1-10
Founded date: 2019
Investors 1
| Date | Name | Website |
| 07.01.2022 | Capital Gr... | capitalgra... |
Mentions in press and media 1
| Date | Title | Description | Category | Author | Source |
| - | Apmonia Th... | “New ways of helping patients ... | - | - | fastfounde... |